Handelsavisen
prelaunch
Companies Consumer Cyclicals 300622.SZ
30
300622.SZ Shenzhen Stock Exchange Miscellaneous Specialty Retailers

Doctorglasses Chain Co Ltd

¥24,79
Open in Charts → Attach watcher ⌖
CNY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,84 %
Op margin
14,2 %
ROE
16,4 %
Net margin
10,9 %
Debt / equity
0,20
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Doctorglasses Chain Co Ltd operates as a specialty retailer in the eyewear industry, offering a range of prescription and non-prescription glasses, contact lenses, and related services to consumers.

Business. Doctorglasses Chain Co Ltd (300622.SZ) is a miscellaneous specialty retailer listed on the Shenzhen Stock Exchange. The company operates within the Consumer Cyclicals sector, focusing on product sales. Specific details regarding its operating segments and geographic mix are not available.

Classification92 %
SectorConsumer Cyclicals
Business sectorRetailers
IndustryMiscellaneous Specialty Retailers
ActivityRetailers
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
16,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 300622.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary · THIS SECTOR+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 300622.SZ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Doctorglasses Chain Co Ltd (300622.SZ) is a miscellaneous specialty retailer listed on the Shenzhen Stock Exchange. The company operates within the Consumer Cyclicals sector, focusing on product sales. Specific details regarding its operating segments and geographic mix are not available.

    Classification92 %
    SectorConsumer Cyclicals
    Business sectorRetailers
    IndustryMiscellaneous Specialty Retailers
    ActivityRetailers
    AI synthesis
    GENERATED

    The company maintains a relatively strong liquidity position, with a current ratio of 2.88, indicating that it has sufficient current assets to cover its current liabilities more than two and a half times over. However, the liquidity risk is rated as medium, and the company has a negative net cash position after subtracting total debt, which could pose a challenge in the short term. The debt-to-equity ratio of 0.2 suggests a conservative capital structure, with a relatively low proportion of debt compared to equity.

    In terms of profitability, the company's return on equity (ROE) of 16.36% and return on assets (ROA) of 10.95% are both above the industry median for specialty retailers, indicating strong returns relative to its equity and asset base. The operating margin, calculated as operating income of 193.46 million CNY on revenue of 1.36 billion CNY, is 14.22%, which is also above the industry median. This suggests that the company is effectively managing its operating costs and generating solid returns from its core operations.

    The company's geographic and segment exposure is not explicitly detailed in the available data, but as a specialty retailer in the eyewear industry, it is likely concentrated in domestic markets. The lack of detailed segment reporting limits the ability to assess the diversification of its revenue streams. However, the company's revenue of 1.36 billion CNY in the latest period suggests a significant presence in the market.

    Looking ahead, the company is expected to maintain a stable growth trajectory, with no specific numeric deltas provided for the current or next fiscal year. The company's free cash flow of 234.58 million CNY and operating cash flow of 296.96 million CNY indicate strong cash generation capabilities, which should support continued operations and potential reinvestment. The capital expenditure of -20.67 million CNY suggests that the company is not currently investing heavily in new assets, which may indicate a focus on maintaining existing operations rather than expansion.

    The company's risk profile is characterized by a low dilution potential, with no significant dilution sources identified in the available data. The risk assessment indicates a low probability of near-term dilution, and no expected timeframe for dilution pressure. The company's conservative capital structure and strong cash flow generation reduce the likelihood of needing to issue additional shares in the near term. However, the negative net cash position after subtracting total debt is a key flag that should be monitored.

    Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The company's financial performance and risk profile suggest a stable and well-managed business, but the lack of detailed segment and geographic reporting limits the ability to fully assess its exposure to different markets and product lines. The company's strong cash flow and profitability metrics indicate a solid financial foundation, but continued monitoring of its liquidity position and capital structure is advisable.

    Key takeaways
    • The company has a strong return on equity (16.36%) and return on assets (10.95%), indicating effective use of capital and assets.
    • The company maintains a conservative capital structure with a debt-to-equity ratio of 0.2, suggesting a low reliance on debt financing.
    • The company's liquidity position is strong, with a current ratio of 2.88, but it has a negative net cash position after subtracting total debt.
    • The company's free cash flow of 234.58 million CNY and operating cash flow of 296.96 million CNY indicate strong cash generation capabilities.
    • The company has a low dilution potential, with no significant dilution sources identified in the available data.
    • The company's risk profile is characterized by a low probability of near-term dilution and a medium liquidity risk.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥24,79
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    ¥908.2M
    Net cash
    -¥185.1M
    Current ratio
    2.9
    Debt / equity
    0.2
    ROA
    10.9%
    ROE
    16.4%
    Cash conversion
    200.0%
    CapEx / revenue
    -1.5%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    12-month price target¥51,80 · Median ¥51,80
    Low ¥51,80High ¥51,80

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low¥51,80
    Mean¥51,80
    Median¥51,80
    High¥51,80
    Spot¥24,79
    +109.0 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin14,2 %Above P75
    Net Margin10,9 %Above P75
    ROE16,4 %Above P75
    Capex / Rev-1,5 %Above median
    D/E0,20Above median
    Cash Conv2,00Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • Doctorglasses Chain Co Ltd Market data — financials · 2026-05-26
    • Doctorglasses Chain Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    300622.SZCanonical
    Shenzhen Stock Exchange · CNY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage